| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc. | Veligrotug (VRDN-001) - (THRIVE-2) | Thyroid Eye Disease (TED) | PDUFA priority review | Ongoing | Intravenous | Opthalmic |
| Viridian Therapeutics Inc. | VRDN-001 - (THRIVE) | Active Thyroid Eye Disease (TED) | PDUFA priority review | Ongoing | Intravenous | Opthalmic |
| Viridian Therapeutics Inc. | VRDN-003 - (REVEAL-2) | Chronic Thyroid Eye Disease (TED) | Phase 3 | Ongoing | Intravenous | Opthalmic |
| Viridian Therapeutics Inc. | VRDN-003 - (REVEAL-1) | Active and Chronic Moderate-to-Severe Thyroid Eye Disease | Phase 3 | Trial Planned | Intravenous | Opthalmic |
| Virpax Pharmaceuticals Inc. | Probudur | Post-operative pain | Phase 2 | Data Released | Infiltration | Non-Opioid Analgesic |
| Vistagen Therapeutics Inc. | PH94B - (PALISADE-4) | Social Anxiety Disorder (SAD) | Phase 3 | Ongoing | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B - (PALISADE-1) | Social Anxiety Disorder (SAD) | Phase 3 | Trial Completed | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B - (PALISADE-3) | Social Anxiety Disorder (SAD) | Phase 3 | Data Released | Intranasal | Psychiatric |